Company news
Sinocelltech Group Limited Class A (SSE:688520) news
Sinocelltech Group Limited Class A news releases on 6ix. Latest, Sep 14, 2026: "Sinocelltech Group Limited"Announcement on Shareholding Reduction Plan…
Press releases & updates
"Sinocelltech Group Limited"Announcement on Shareholding Reduction Plan of Shareholder
September 13, 2026
"Sinocelltech Group Limited"Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 8, 2026
"Sinocelltech Group Limited"Semi-annual Report for 2026
August 28, 2026
"Sinocelltech Group Limited"Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of the Controlled Subsidiary's Product SCTB10
August 19, 2026
Announcement on Changing Registered Capital, Amending the Articles of Association and Handling Industrial and Commercial Change Registration
June 18, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 13, 2026
Report for Q1 2026
April 29, 2026
2025 Annual Report
April 22, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
April 20, 2026
Announcement on the Results of Issuing Shares to Specific Objects and Changes in Capital Stock in 2025
April 9, 2026
Announcement on Using Temporarily Idle Raised Funds for Phased Cash Management
April 2, 2026
Announcement on Signing Tripartite Supervision Agreement for Deposit of Raised Fund in Special Account
April 1, 2026
Indicative Announcement on the Issuance of Shares to Specific Objects in 2025
March 31, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
March 20, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Obtaining CSRC Registration Approval for Issuing Stocks to Specific Objects in 2025
January 5, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 29, 2025
Announcement on Obtaining Government Subsidies
December 25, 2025
Announcement on External Donations
December 12, 2025
Announcement on Receiving Notice of Review Opinions from Shanghai Stock Exchange for Application for the Issuance of A-shares to Specific Objects in 2025
December 5, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 7, 2025
Report for Q3 2025
October 30, 2025
Indicative Announcement on Reply to Letter of Review and Inquiry on Application Documents for Shares Issuance to Specific Objects
October 14, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Acceptance of Application for Issuance of A-shares to Specific Objects in 2025 by SSE
August 26, 2025
Announcement on Voluntary Disclosure of the Receipt of the Drug Clinical Trial Approval Notice for Product SCT640C by a Holding Subsidiary
July 24, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 4, 2025
Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale and Result of Shareholding Reduction
July 2, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval of Drug Clinical Trial for Holding Subsidiary's Product SCTB39G
June 25, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
June 23, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval of Drug Clinical Trial for Holding Subsidiary's Product SCTB39-1
June 17, 2025
Indicative Announcement on Changes in Shareholder's Equity
June 6, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
June 5, 2025
Announcement on Resolution of the 1st Meeting of the 3rd Board of Directors
May 16, 2025
Announcement on Realizing Profitability for the 1st Time and Canceling Stock Abbreviation U
April 25, 2025
Announcement on Shareholding Reduction Plan for Shareholders
April 22, 2025
Announcement on Resignation of Deputy General Manager
March 31, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Holding Subsidiary's Product SCTT11
March 6, 2025
Announcement on Voluntary Disclosure of Drug Registration Certificate Obtained by Holding Subsidiary
February 28, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 24, 2025
Announcement on Expected Gains in Annual Performance for 2024
January 17, 2025
Announcement on Resolution of the 3rd Extraordinary General Meeting in 2024
December 30, 2024
Announcement on the Addition of New Office Address and Change of Investor Contact Phone Number
December 20, 2024
Notice on Convening the 3rd Extraordinary General Meeting in 2024
December 13, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 6, 2024
Report for Q3 2024
October 28, 2024
Announcement on the Company's Voluntary Disclosure of Approval Notice for the Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine SCTV02 by the Company's Holding Subsidiary
October 22, 2024
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024
September 6, 2024